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Abstract Cardiomyocytes exhibit robust proliferative
activity during development. After birth, cardiomyocyte
proliferation is markedly reduced. Consequently, regener-
ative growth in the postnatal heart via cardiomyocyte
proliferation (and, by inference, proliferation of stem-cell-
derived cardiomyocytes) is limited and often insufﬁcient to
affect repair following injury. Here, we review studies
wherein cardiomyocyte cell cycle proliferation was
induced via targeted expression of cyclin D2 in postnatal
hearts. Cyclin D2 expression resulted in a greater than 500-
fold increase in cell cycle activity in transgenic mice as
compared to their nontransgenic siblings. Induced cell
cycle activity resulted in infarct regression and concomi-
tant improvement in cardiac hemodynamics following
coronary artery occlusion. These studies support the notion
that cell-cycle-based strategies can be exploited to drive
myocardial repair following injury.
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Introduction: Cardiomyocyte Cell Cycle Activity
Many forms of cardiac disease are associated with the
absence or loss of functional myocardium; for example,
congenital diseases such as septal defects and hypoplastic
chamber syndromes in many instances exhibit reduced
levels of cell cycle activity during development, resulting
in a deﬁcit of cardiomyocytes. After birth, acquired injuries
such as ischemia/reperfusion during surgical interventions
or myocardial infarction, viral myocarditis, and anthracy-
cline cardiotoxicity can all lead to cardiomyocyte loss and
diminished cardiac function. The persistence of compro-
mised cardiac function following congenital and acquired
cardiac injury, particularly in postnatal hearts, indicates
that the intrinsic regenerative reserve of the myocardium is
at best limited.
Despite the absence of overt cardiac regeneration in
postnatal hearts, many studies have been performed to
determine if cardiomyocytes have the capacity to prolif-
erate after birth and to determine if stem cells with
cardiomyogenic potential persist in postnatal hearts. If such
capacities were present in the postnatal heart, it might be
possible to therapeutically manipulate the relevant path-
ways to promote regenerative growth. Pioneering work
from Pavel Rumiantsev in the 1970s and 1980s utilized a
number of experimental approaches to quantitate the levels
of cardiomyocyte DNA replication and cell division during
development and following injury in a large number of
species, including humans [15]. These studies revealed that
the level of cardiomyocyte DNA synthesis and cell division
decreases rapidly after birth. Although cardiomyocyte cell
cycle activity was detectable in juvenile and adult hearts,
the level was exceedingly low. These ﬁndings are sup-
ported by the bulk of subsequent studies [18]. As it is likely
that stem-cell-derived cardiomyocytes would also exhibit
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omyogenic activity in postnatal hearts is also limited.
Indeed, cell fate studies in mice [7] and humans [1] support
this conclusion.
Given the low levels of intrinsic cardiac regeneration,
considerable effort has been employed to experimentally
activate cardiomyogenic stem cell activity and/or car-
diomyocyte cell cycle activity, with the hopes that these
manipulations could be translated to human hearts [13].
These studies have been greatly aided by the use of gene
transfer techniques and, in particular, the use of geneti-
cally altered mice with either gain- or loss-of-function
modiﬁcations. Using this approach, a number of genes
have been identiﬁed as key cardiomyocyte cell cycle
regulatory proteins [10]. In several instances, manipula-
tion of these genes was able to promote regenerative
growth following myocardial injury in postnatal hearts.
This article will focus on our laboratory’s studies of the
use of cyclin D2 to promote regenerative myocardial
growth.
Forced Transit of the Restriction Point Can Induce
Cardiomyocyte Cell Cycle Progression
Restriction point transit constitutes the key regulatory step
in the commitment to a new round of cell division.
Restriction point transit is regulated largely by the activity
of cyclin-dependent kinase 4 (CDK4) and its obligate
cofactors, the D-type cyclins [3, 16]. D-Type cyclin
expression is induced by growth factors; when D-type
cyclins accumulate in the nucleus, they bind to and activate
CDK4. This active cyclin D/CDK4 complex phosphory-
lates members of the retinoblastoma (RB) gene family,
which in turn frees members of the E2F transcription
family to initiate a new round of cell cycle activity.
There are three D-type cyclins in mammals, designated
cyclin D1, D2, and D3. All three are expressed in the
developing heart and all three are rapidly downregulated
after birth in parallel with the decreased levels of cardio-
myocyte proliferation in postnatal hearts [20, 21]. In an
effort to induce restriction point transit (and, hopefully, cell
cycle progression) in postnatal mouse hearts, we generated
transgenic mice expressing cyclin D1, D2, or D3 under the
regulation of the cardiomyocyte-restricted myosin heavy
chain (MHC) promoter [11, 21]. Although all three trans-
genic models exhibited similar postnatal cell cycle kinetics
under baseline conditions, only mice expressing cyclin D2
(designated MHC-cycD2 mice) exhibited sustained cell
cycle activity following injury. Consequently, this review
focuses on the MHC-cycD2 model. Immune histology
analyses revealed high levels of nuclear cyclin D2
expression in the MHC-cycD2 transgenic hearts but not in
their nontransgenic siblings (Fig. 1, upper panels). Inter-
estingly, cyclin D2 expression was accompanied by a
marked induction of the endogenous CDK4 gene product
(Fig. 1, middle panels).
To monitor the impact of cyclin D2 expression on
postnatal cardiomyocyte cell cycle activity, the MHC-
cycD2 mice were intercrossed with MHC-nLAC mice,
which express a nuclear b-galactosidase reporter under the
control of the MHC promoter [19]. At 12 weeks of age,
progeny from the cross were given a single injection of
tritiated thymidine. Four hours later, the mice were sacri-
ﬁced; the hearts were harvested, sectioned, stained with
X-GAL (which produces a blue signal when metabolized
by b-galactosidase), and then coated with photographic
Fig. 1 Transgene expression and cardiomyocyte DNA synthesis in
postnatal MHC-cycD2 hearts. Heart sections from MHC-cycD2 mice
and their nontransgenic littermates were subjected to anti-cyclin D2
(upper panels) and anti-CDK4 (middle panels) immune histology
(horseradish peroxidase-conjugated secondary antibody, dark brown
signal from diaminobenzidine reaction). Cyclin D2 expression results
in a concomitant induction of the endogenous CDK4 gene product in
transgenic hearts. Heart sections from MHC-cycD2/MHC-nLAC
double transgenic mice and their MHC-nLAC single transgenic
littermates were processed for cardiomyocyte DNA synthesis assay
(mice received an injection of tritiated thymidine prior to sacriﬁce).
The presence of silver grains over blue nuclei is indicative of
cardiomyocyte DNA synthesis and is readily seen in sections from
mice carrying the MHC-cycD2 transgene
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123emulsion. After the photographic emulsion is developed,
the presence of silver grains (due to tritiated thymidine
exposure of emulsion) over blue nuclei (due to cardiomy-
ocyte-restricted expression of the nuclear b-galactosidase)
is indicative of cardiomyocyte DNA synthesis. Mice
inheriting both the MHC-cycD2 and MHC-nLAC trans-
genes had a cardiomyocyte tritiated thymidine labeling
index of 0.26% [11]; an example of an S-phase cardio-
myocyte using this assay is shown in Fig. 1 (lower panels).
In contrast, mice inheriting the MHC-nLAC transgene
alone had tritiated thymidine labeling index of 0.0005%
[11, 17], although noncardiomyocyte DNA synthesis could
easily be detected in these animals. Thus, expression of
cyclin D2 is sufﬁcient to drive DNA synthesis in postnatal
cardiomyocytes.
Cyclin D2 Expression Promotes Structural Repair
Following Myocardial Infarction
Given that the MHC-cycD2 mice exhibit an approximately
500-fold increase in tritiated thymidine labeling index as
compared to their nontransgenic siblings, additional
experiments were performed to determine if cardiomyocyte
cell cycle induction could reverse myocardial injury in
postnatal hearts. Accordingly, MHC-cycD2 mice and their
nontransgenic littermates were subjected to permanent
coronary artery occlusion [6]. Hearts were harvested at 7,
60, and 180 days postinjury, and infarct size was deter-
mined using the approach developed by Pfeffer and
colleagues [12]. In nontransgenic mice, approximately
53% of the left ventricle was infarcted at 7 days postinjury
(Fig. 2a). Infarct size remained constant through 180 days
postinjury, although there was a slight trend toward infarct
expansion. At 7 days postinjury, MHC-cycD2 transgenic
mice exhibited a similar infarct size, as was seen in their
nontransgenic littermates, indicating that expression of
cyclin D2 was not acutely cardioprotective. However, a
marked reduction in infarct size was seen at 60 and
180 days postinjury.
Structural repair was readily apparent when examining
survey micrographs of transverse sections from the MHC-
cycD2 transgenic hearts sampled at 1-mm intervals from
the apex to the base (Fig. 2b). The sections were stained
Fig. 2 Expression of cyclin D2
results in infarct regression. a
Infarct size in nontransgenic and
MHC-cycD2 transgenic mice at
7, 6, and 180 days postinjury.
Asterisks indicate statistical
signiﬁcance between MHC-
cycD2 hearts and. noninfarcted
hearts at the indicated time
point. b Representative sections
from infarcted MHC-cycD2
transgenic hearts and their
nontransgenic siblings at 7 and
180 days postinjury. Sections
were sampled at 1-mm intervals
from the apex to the base and
were stained with Azan
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stains gray). At 7 days postinjury, transmural damage was
apparent from the apex to the base. However, by 180 days
postinjury, cardiomyocytes could be detected in apically
located sections of MHC-cycD2 hearts. Because these
apical regions were devoid of cardiomyocytes at 7 days
postinjury, they have been designated as regenerated
myocardium. In contrast, apical regions in nontransgenic
hearts lacked any evidence of regenerative growth over the
course of the experiment.
Consistent with this interpretation, MHC-cycD2 hearts
exhibited sustained, high levels of cardiomyocyte DNA
synthesis (ranging between 0.5% and 1% following a
single injection of tritiated thymidine), and cardiomyo-
cytes with phosphorylated histone H3 immune reactivity
(a marker for mitosis [23]) were readily detected [11].
Collectively, these data demonstrate that cyclin D2
expression resulted in a remarkable degree of regenerative
growth following injury.
Cyclin D2 Expression Promotes Functional Recovery
Following Myocardial Infarction
Given the structural recovery observed in the infarcted
MHC-cycD2 mice, it is likely that there would be a con-
comitant improvement in cardiac function provided that the
newly regenerated myocardium participated in a functional
syncytium with the remote, noninfarcted myocardium.
Immune histology analyses revealed that regenerated
cardiomyocytes were connected to one another via well-
developed junctional complexes containing connexin43
(the major component of the cardiac gap junction; Fig. 3a).
To determine if the regenerated myocardium was func-
tionally integrated, MHC-cycD2 hearts harvested at
180 days postinjury were perfused on a Langendorff
apparatus, and the apically located (i.e., regenerated)
myocardium was imaged for the presence of intracellular
calcium transients using the calcium-sensing dye rhod-2 in
combination with two-photon laser scanning microscopy
Fig. 3 Regenerated myocardium in MHC-cycD2 hearts is function-
ally integrated. Samples are from MHC-cycD2 hearts at 180 days
postinfarction. a Apically located regenerated cardiomyocytes are
well developed (left panel, Azan stain) and are interconnected via
well-developed junctional complexes containing anti-connexin43
immune reactivity (right panel, horseradish peroxidase-conjugated
secondary antibody, dark brown signal from diaminobenzidine
reaction). b Intracellular calcium transients (as evidenced via changes
in the ﬂuorescence of the calcium-sensing dye rhod2) recorded from
three apically located cardiomyocytes in the regenerated myocardium
(left panels). Intracellular calcium transients in cardiomyocytes
located in the regenerated myocardium were in synchrony with and
indistinguishable from those in the remote myocardium (right panels)
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123[14]. Intracellular calcium transients were readily observed
in the regenerated myocardium during sinus rhythm
(recordings from three adjacent cardiomyocytes are shown
in Fig. 3b, left panels). These intracellular calcium tran-
sients were in synchrony with and indistinguishable from
those in the remote, noninfarcted myocardium (Fig. 3b,
right panels). These data indicate that the regenerated
myocardium can participate in a functional syncytium with
the host myocardium.
To determine the impact of myocardial regeneration on
cardiac hemodynamics, MHC-cycD2 mice and their non-
transgeniclittermatesweresubjectedtopermanentcoronary
artery occlusion. At 7, 60, and 180 days postinjury,the mice
were anaesthetized and ventilated, the left ventricular was
accessed via the right common carotid artery, and pressure–
volume relationships were recorded using a 1.4-French
Millar catheter [6]. These experiments employed the same
series of mice used earlier for infarct size measurement
(hemodynamic measurements were performed prior to sac-
riﬁce). Pressure–volume analyses were also performed in
time-point-matched, sham-infarcted mice.
Cardiac function was markedly suppressed in the
infarcted nontransgenic animals at all times analyzed.
Figure 4 shows the values calculated for the left ventricular
peak positive developed pressure/end diastolic volume
relationship (dP/dtmax/EDV, left panel, open bars) and the
end systolic pressure–volume relationship (ESPVR, right
panel, open bars). Functional parameters were normalized
to the values obtained from time-point-matched, sham-
infarcted mice. At 7 days postinfarction, cardiac function
in the MHC-cycD2 was suppressed to a similar extent as
was seen for the nontransgenic animals. However, a
marked and progressive increase in cardiac function was
apparent at 60 and 180 days postinfarction (Fig. 4, closed
bars). Remarkably, at the 180-day time point, dP/dtmax/
EDV and ESPVR were not statistically different in
infarcted versus sham-infarcted MHC-cycD2 mice
(1172.7 ± 222.7 vs. 1336 ± 119 mm Hg/s/ll and
29.0 ± 3.1 vs. 31.2 ± 2.8 mm Hg/ll, respectively).
Summary and Future Directions
The data reviewed here indicate that constitutive expres-
sion of cyclin D2 is sufﬁcient to promote cardiomyocyte
cell cycle activity in postnatal hearts and that this cell cycle
activity results in myocardial regeneration and functional
recovery following injury. To date, a number of gene
products have been shown to promote structural and/or
functional recovery in injured hearts; for example, deletion
of the p38 MAP kinase gene results in FGF1-inducible cell
cycle progression in postnatal cardiomyocytes in vitro and
in vivo [4]. Transient pharmacologic inhibition of p38
MAP kinase, in combination with FGF1 treatment, resulted
in improved cardiac structure and function at 3 months
postinfarction in adult rats [5]; however, the degree to
which proproliferation, antiapoptotic and/or antihypertro-
phic activities contributed the observed improvement is not
clear. Transgenic mice expressing cyclin A2 (which can
regulate both restriction point transit and mitosis entry)
exhibited enhanced cardiomyocyte cell cycle activity in
early postnatal life, but not in adults [2]. Viral delivery of
cyclin A2 in infarcted rat hearts had a positive impact on
cardiac structure and function [24], although the cell type
responsible for the observed improvement was not clear.
As reported elsewhere, genetic deletion of c-kit renders
postnatal cardiomyocytes able to reenter the cell cycle
following injury [8]. Finally, cardiomyocyte-restricted
deletion of the RB gene, in the presence of global deletion
of p130 (another member of the RB gene family), gave rise
to cardiomyocyte hypertrophy and hyperplasia in postnatal
hearts [9].
These are but a few examples of genetic pathways that
can be exploited to induce cell cycle activity in postnatal
cardiomyocytes. However, there remain a number of issues
that must be experimentally addressed to validate these
genes as potential targets to induce regenerative growth;
for example, most studies utilized genetic manipulations
that occurred prior to cardiomyocyte terminal differentia-
tion. Hence, it is possible that similar manipulation in adult
cardiomyocytes might not have the same result. This is
likely not the case with targets aimed at modulating
restriction point transit, as viral delivery of a cyclin D1
molecule carrying a nuclear localization sequence, in
combination with CDK4, was sufﬁcient to induce cardio-
myocyte cell cycle activity in adult rat hearts [22].
Similarly, as indicated earlier, pharmacologic modulation
of p38 MAP kinase and FGF1 resulted in cell cycle pro-
gression in adult hearts. Perhaps even more important is to
Fig. 4 Left ventricular performance was assessed by pressure–
volume measurements. The left panel shows the left ventricular peak
positive developed pressure/end diastolic volume (dP/dtmax/EDV)
relationship for nontransgenic (open bars) and MHC-cycD2 mice
(closed bars) at 7, 60, and 180 days after myocardial infarction. The
values shown were normalized to those obtained from sham-operated
mice from the same time points. The right panel shows the end
systolic pressure–volume relationship (EDPVR)
714 Pediatr Cardiol (2009) 30:710–715
123determine if the genetic pathways in question are also
operative in human cardiomyocytes. The ability to isolate
and engraft cardiomyogenic precursors from human
embryonic stem cells [25] as well as other cardiomyogenic
precursors will greatly facilitate such analyses. Finally,
once manipulation of a given genetic pathway is validated
as a target for inducing regenerative growth, it would be
highly desirable to develop molecules that mimic the
genetic modiﬁcation, thereby obviating the need for gene
transfer-based interventions.
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